Efficacy of Upadacitinib in Psoriatic Arthritis and Rheumatoid Arthritis: The OPTIMA Study for Optimizing Imaging in Arthritis Follow-Up

What this Trial Is About

Researchers are investigating how imaging techniques like ultrasound and magnetic resonance imaging, along with clinical, laboratory, and patient-reported outcome measures, change over the first six months in people with active Psoriatic Arthritis or Rheumatoid Arthritis starting treatment with the drug Upadacitinib. This study focuses on understanding these changes in patients beginning this therapy to better monitor disease activity and treatment response. This observational study enrolls patients with active Psoriatic Arthritis or Rheumatoid Arthritis who are prescribed Upadacitinib by their doctors. Participants will be evaluated at treatment start and followed up at 2 weeks, 1 month, 3 months, and 6 months. Clinical assessments, laboratory tests, and ultrasound of affected joints will be done at each visit except the 2-week check. For those with axial disease, MRI scans will be performed at baseline and after 6 months if clinically indicated. During the study, data from clinical exams, lab tests, imaging, and patient questionnaires will be collected to measure disease activity and treatment effects. The main outcome is the change in ultrasound synovitis scores from baseline to 24 weeks. Other measures include various ultrasound scores, MRI indices, joint counts, inflammation markers, patient and physician assessments, and adverse events. This comprehensive follow-up aims to provide detailed information about disease progression and response to Upadacitinib over six months.

Efficacy Of Upadacitinib In Psoriatic Arthritis And Comparison To Rheumatoid Arthritis.